Immunologic, microbial, and epithelial interactions in atopic dermatitis

Because Atopic dermatitis has been identified as a heterogeneous disease with activation of more than 1 inflammatory pathway rather than a uniform condition with a single pathogenic immune axis such as psoriasis, the 2 models are likely to be relevant, with varying nuances depending on the AD population being evaluated

Patrick M. Brunner; Donald Y.M. Leung; Emma Guttman-Yassky

2017

Scholarcy highlights

  • Because Atopic dermatitis has been identified as a heterogeneous disease with activation of more than 1 inflammatory pathway rather than a uniform condition with a single pathogenic immune axis such as psoriasis, the 2 models are likely to be relevant, with varying nuances depending on the AD population being evaluated
  • The age of onset can be quite different, with a minority of patients showing the advent of late-onset AD during adulthood, a subset that can have some diagnostic challenges owing to atypical clinical presentation
  • These data have led to the development of new therapeutics that have already been approved or show promise in clinical trials
  • IL-31 blockade seems to be a promising strategy for AD and possibly for other pruritic skin diseases
  • Future clinical trials with targeted therapies will likely further contribute to the elucidation of AD skin biology
  • Results might optimize treatment approaches and most likely will increase our understanding of Atopic dermatitis disease heterogeneity

Need more features? Save interactive summary cards to your Scholarcy Library.